EP4043455A1 — Bicyclic compound that acts as crbn protein regulator
Assigned to Medshine Discovery Inc · Expires 2022-08-17 · 4y expired
What this patent protects
A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.
USPTO Abstract
A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.
Drugs covered by this patent
- Ecclock (SOFPIRONIUM BROMIDE) · Kaken Pharmaceutical
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.